|
1
|
Luciani A, Marra A, Toschi L, Cortinovis
D, Fava S, Filipazzi V, Tuzi A, Cerea G, Rossi S, Perfetti V, et
al: Efficacy and safety of Anti-PD-1 immunotherapy in patients aged
≥ 75 years with non-small-cell lung cancer (NSCLC): An Italian,
multicenter, retrospective study. Clin Lung Cancer. 21:e567–e571.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Altan M, Singhi EK, Worst M, Carter BW,
Leung CH, Lee JJ, Presley CJ, Lewis J, Rinsurongkawong W,
Rinsurongkawong V, et al: Clinical effectiveness and safety of
anti-PD-(L)1 therapy among older adults with advanced non-small
cell lung cancer. Clin Lung Cancer. 23:236–243. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fossella FV, DeVore R, Kerr RN, Crawford
J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, et al:
Randomized phase III trial of docetaxel versus vinorelbine or
ifosfamide in patients with advanced non-small-cell lung cancer
previously treated with platinum-containing chemotherapy regimens.
The TAX 320 non-small cell lung cancer study group. J Clin Oncol.
18:2354–2362. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shepherd FA, Dancey J, Ramlau R, Mattson
K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R,
et al: Prospective randomized trial of docetaxel versus best
supportive care in patients with non-small-cell lung cancer
previously treated with platinum-based chemotherapy. J Clin Oncol.
18:2095–2103. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Anderson H, Hopwood P, Stephens RJ,
Thatcher N, Cottier B, Nicholson M, Milroy R, Maughan TS, Falk SJ,
Bond MG, et al: Gemcitabine plus best supportive care (BSC) vs. BSC
in inoperable non-small cell lung cancer-a randomized trial with
quality of life as the primary outcome. UK NSCLC Gemcitabine Group.
Non-small cell lung cancer. Br J Cancer. 83:447–453. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ciuleanu T, Brodowicz T, Zielinski C, Kim
JH, Krzakowski M, Laack E, Wu YL, Bover I, Begbie S, Tzekova V, et
al: Maintenance pemetrexed plus best supportive care versus placebo
plus best supportive care for non-small-cell lung cancer: A
randomised, double-blind, phase 3 study. Lancet. 374:1432–1440.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ardizzoni A, Tiseo M, Boni L, Vincent AD,
Passalacqua R, Buti S, Amoroso D, Camerini A, Labianca R,
Genestreti G, et al: Pemetrexed versus pemetrexed and carboplatin
as second-line chemotherapy in advanced non-small-cell lung cancer:
Results of the GOIRC 02–2006 randomized phase II study and pooled
analysis with the NVALT7 trial. J Clin Oncol. 30:4501–4507. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pérol M, Chouaid C, Pérol D, Barlési F,
Gervais R, Westeel V, Crequit J, Léna H, Vergnenègre A, Zalcman G,
et al: Randomized, phase III study of gemcitabine or erlotinib
maintenance therapy versus observation, with predefined second-line
treatment, after cisplatin-gemcitabine induction chemotherapy in
advanced non-small-cell lung cancer. J Clin Oncol. 30:3516–3524.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kawaguchi T, Ando M, Asami K, Okano Y,
Fukuda M, Nakagawa H, Ibata H, Kozuki T, Endo T, Tamura A, et al:
Randomized phase III trial of erlotinib versus docetaxel as second-
or third-line therapy in patients with advanced non-small-cell lung
cancer: Docetaxel and Erlotinib lung cancer trial (DELTA). J Clin
Oncol. 32:1902–1908. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gandhi L, Rodríguez-Abreu D, Gadgeel S,
Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ,
Powell SF, et al: Pembrolizumab plus chemotherapy in metastatic
non-small-cell lung cancer. N Engl J Med. 378:2078–2092. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Paz-Ares L, Luft A, Vicente D, Tafreshi A,
Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, et
al: Pembrolizumab plus chemotherapy for squamous non-small-cell
lung cancer. N Engl J Med. 379:2040–2051. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Schoenfeld JD, Giobbie-Hurder A,
Ranasinghe S, Kao KZ, Lako A, Tsuji J, Liu Y, Brennick RC, Gentzler
RD, Lee C, et al: Durvalumab plus tremelimumab alone or in
combination with low-dose or hypofractionated radiotherapy in
metastatic non-small-cell lung cancer refractory to previous
PD(L)-1 therapy: An open-label, multicentre, randomised, phase 2
trial. Lancet Oncol. 23:279–291. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ochoa-de-Olza M, Bourhis J, Coukos G and
Herrera FG: Low-dose irradiation for reversing immunotherapy
resistance: How to translate? J Immunother Cancer. 10:e0049392022.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rauwerdink DJW, Molina G, Frederick DT,
Sharova T, van der Hage J, Cohen S and Boland GM: Mixed response to
immunotherapy in patients with metastatic melanoma. Ann Surg Oncol.
27:3488–3497. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shroff GS, Strange CD, Altan M, Carter BW,
Ahuja J, Godoy MCB, Truong MT and Vlahos I: Post-immunotherapy
imaging in lung cancer. Clin Radiol. 77:44–57. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xu Y, Li H and Fan Y: Progression
patterns, treatment, and prognosis beyond resistance of responders
to immunotherapy in advanced non-small cell lung cancer. Front
Oncol. 11:6428832021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Reinhorn D, Jacobi O, Icht O, Dudnik E,
Rotem O, Zer A and Goldstein DA: Treatment beyond progression with
immune checkpoint inhibitors in non-small-cell lung cancer.
Immunotherapy. 12:235–243. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ge X, Zhang Z, Zhang S, Yuan F, Zhang F,
Yan X, Han X, Ma J, Wang L, Tao H, et al: Immunotherapy beyond
progression in patients with advanced non-small cell lung cancer.
Transl Lung Cancer Res. 9:2391–2400. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Enomoto T, Tamiya A, Matsumoto K, Adachi
Y, Azuma K, Inagaki Y, Kouno S, Taniguchi Y, Saijo N, Okishio K, et
al: 79P-Nivolumab treatment beyond progression disease in advanced
non-small cell lung cancer. Ann Oncol. 30:xi282019. View Article : Google Scholar
|
|
21
|
Czarnecka AM, Sobczuk P, Rogala P, Świtaj
T, Placzke J, Kozak K, Mariuk-Jarema A, Spałek M, Dudzisz-Śledź M,
Teterycz P, et al: Efficacy of immunotherapy beyond RECIST
progression in advanced melanoma: A real-world evidence. Cancer
Immunol Immunother. 71:1949–1958. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Klemen ND, Wang M, Feingold PL, Cooper K,
Pavri SN, Han D, Detterbeck FC, Boffa DJ, Khan SA, Olino K, et al:
Patterns of failure after immunotherapy with checkpoint inhibitors
predict durable progression-free survival after local therapy for
metastatic melanoma. J Immunother Cancer. 7:1962019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Corbaux P, Maillet D, Boespflug A,
Locatelli-Sanchez M, Perier-Muzet M, Duruisseaux M,
Kiakouama-Maleka L, Dalle S, Falandry C and Péron J: Older and
younger patients treated with immune checkpoint inhibitors have
similar outcomes in real-life setting. Eur J Cancer. 121:192–201.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nabrinsky E, Macklis J and Bitran J: A
review of the abscopal effect in the era of immunotherapy. Cureus.
14:e296202022.PubMed/NCBI
|
|
25
|
Welsh J, Menon H, Chen D, Verma V, Tang C,
Altan M, Hess K, de Groot P, Nguyen QN, Varghese R, et al:
Pembrolizumab with or without radiation therapy for metastatic
non-small cell lung cancer: A randomized phase I/II trial. J
Immunother Cancer. 8:e0010012020. View Article : Google Scholar : PubMed/NCBI
|
